Sign In
Buy BYSI
$1.15
+0.0200 (+1.77%)
At Close: Jul 31, 2026
Beyondspring (BYSI) Gets a Buy Rating from William Blair
06:40pm, Friday, 10'th Jan 2020
In a report issued on January 6,
Andy Hsieh
from William Blair reiterated a
Buy
rating on Beyondspring (
BYSI
–
Research Report
). The company’s shares closed last Monday at $17.64.
According to
T
Kadmon, BeyondSpring gain a bull as Nomura picks up coverage
03:05pm, Friday, 10'th Jan 2020
BeyondSpring (NASDAQ:BYSI) rises 2.7% and Kadmon Holdings (NYSE:KDMN) also gains 2.7% after Nomura Instinet initiates coverage of the two companies at Buy.BeyondSpring is testing plinabulin in mul
Morgan Stanley sees 15% upside in McKesson in premarket analyst action
12:32pm, Friday, 10'th Jan 2020
Aerie Pharmaceuticals (NASDAQ:AERI) initiated with Neutral rating and $27 (6% upside) price target at Bank of America.Aurinia Pharmaceuticals (AUP CN) initiated with Buy rating and C$35.26 (32% upside
BeyondSpring Strengthens Executive Rank for Pipeline Expansion and Commercialization Readiness in China
01:00pm, Monday, 06'th Jan 2020
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced today the ap
BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies
01:00pm, Thursday, 19'th Dec 2019
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the peer reviewed journal Cancer Chemothera
BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update
12:00pm, Wednesday, 18'th Dec 2019
Preparing to Submit NDA in China for Chemotherapy-Induced Neutropenia (“CIN”) in Q1 2020 Plinabulin’s Anti-Cancer and CIN Prevention Mechanism Published in Peer.
BeyondSpring to Host Third-Quarter 2019 Financial Results and Operational Update Conference Call on December 18, 2019
02:01pm, Wednesday, 11'th Dec 2019
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s abstract for its Phase 3 St
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abstracts on the unique mechani
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s novel trial design for Stud
BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources
01:05pm, Wednesday, 06'th Nov 2019
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has appointed Gregg Russo as Se
BeyondSpring Announces Pricing of Ordinary Shares
01:01pm, Friday, 25'th Oct 2019
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology can
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
08:03pm, Thursday, 24'th Oct 2019
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology can
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has enrolled its first patient
BeyondSpring’s Lead Asset, Plinabulin, Granted U.S. Patent Covering Methods of Treating Brain Tumors
12:00pm, Thursday, 17'th Oct 2019
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the United States Patent Office has granted the Company a n
